Table 3.
Observed 3-year survival rate by race and SES, stratified by tumor stage
| Observed 3-year survival rate (95% CI) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Race/ethnicity and SES | Local Stage | Regional Stage | Distant Stage | Unstaged/Missing | ||||
| All-cause | Cancer-specific | All-cause | Cancer-specific | All-cause | Cancer-specific | All-cause | Cancer-specific | |
| Race/ethnicity | ||||||||
| NH-White | 85(84–86) | 92(91–93) | 49(47–52) | 55(53–57) | 13(11–15) | 14(12–16) | 36(33–39) | 42(39–46) |
| NH-Black | 82(79–86) | 88(85–91) | 42(35–49) | 47(40–54) | 16(11–20) | 17(12–22) | 37(27–47) | 44(33–55) |
| NH-API | 85(80–89) | 91(87–95) | 59(49–68) | 64(54–74) | 20(11–30) | 23(13–33) | 34(12–56) | 45(18–72) |
| Hispanic | 90(86–93) | 94(91–97) | 54(45–63) | 62(52–71) | 14(7–22) | 15(8–23) | 39(23–55) | 43(26–60) |
| AI/AN | 86(68–100) | 94(82–100) | 26(3–50) | 28(3–53) | 0 | 0 | 21(0–100) | 21(0–100) |
| Health Insurance | ||||||||
| Employer/Medicare/Private | 85(83–86) | 92(91–93) | 50(47–53) | 55(52–58) | 14(12–16) | 15(12–17) | 38(32–43) | 44(38–50) |
| Government | 83(69–97) | 84(71–98) | 42(19–65) | 51(25–76) | 0 | 0 | 0 | 0 |
| Medicaid/Not-insured | 76(70–81) | 85(80–90) | 47(40–55) | 51(43–59) | 8(3–12) | 9(4–14) | 29(14–44) | 33(16–50) |
| Unknown | 85(84–87) | 93(92–93) | 49(46–52) | 55(52–58) | 14(12–16) | 15(13–18) | 36(32–40) | 43(38–47) |
| Years of Education† | ||||||||
| <12 | 74(72–77) | 85(83–87) | 39(35–42) | 44(40–47) | 10(7–12) | 11(8–13) | 31(27–36) | 38(32–43) |
| 12 | 85(84–87) | 92(91–93) | 49(46–52) | 55(52–58) | 13(11–16) | 14(11–16) | 40(34–45) | 46(40–52) |
| ≥13 | 90(89–91) | 95(95–96) | 59(56–62) | 65(61–68) | 18(15–21) | 20(16–23) | 39(33–45) | 46(40–53) |
| Tumor Sites | ||||||||
| Breast | 90(89–92) | 96(95–97) | 82(80–85) | 88(86–90) | 29(22–36) | 32(24–40) | 48(37–59) | 63(51–76) |
| Colorectal | 81(78–84) | 91(88–93) | 60(57–64) | 67(63–70) | 11(8–14) | 12(9–15) | 33(24–42) | 40(30–50) |
| Prostate* | 89(88–91) | 96(95–96) | - | - | 37(30–44) | 41(34–48) | 63(57–68) | 76(70–81) |
| Lung and bronchus | 43(38–48) | 49(44–55) | 15(13–17) | 17(14–19) | 3(2–4) | 3(2–4) | 10(7–13) | 11(8–15) |
| Cervix | 89(81–97) | 93(87–100) | 59(45–74) | 63(51–78) | 12(0–26) | 12(0–26) | 50(14–86) | 56(19–94) |
| Ovarian | 88(80–96) | 94(88–100) | 74(54–95) | 74(49–77) | 34(28–39) | 37(30–43) | 22(4–39) | 24(6–43) |
| Melanoma of the skin | 91(89–94) | 96(94–98) | 49(34–65) | 56(39–73) | 8(0–22) | 9(0–23) | 90(75–100) | 93(81–100) |
| Urinary bladder | 78(75–81) | 89(86–92) | 28(21–35) | 37(28–46) | 9(0–20) | 10(0–22) | 65(48–83) | 74(56–91) |
*
For prostate cancer, localized/regional stages were combined in SEER and were here reported in localized stage.
†
not reported for 3 cases with missing education.